Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864273 | 0.86 | CES2 (0.46) | CES2CES1CA2P2RX7RIPK1 | |
| SCHEMBL892933 | 0.84 | CES2 (0.45) | CES2CES1CA2P2RX7RIPK1 | |
| SCHEMBL29459927 | 0.84 | CES2 (0.45) | CES2CES1CA2P2RX7RIPK1 | |
| SCHEMBL30517175 | 0.82 | CES2 (0.43) | CES2CES1CA2P2RX7RIPK1 | |
| Methyl Alcohol SCHEMBL17241181 | 0.81 | RIPK1 (0.44) | CES2CES1CA2P2RX7RIPK1 | |
| SCHEMBL31552004 | 0.76 | RIPK1 (0.42) | CA2P2RX7RIPK1 | |
| SCHEMBL8209127 | 0.76 | CXCL8 (0.53) | CXCL8ALDH1A1 | |
| SCHEMBL5419671 | 0.75 | CES2 (0.43) | CES2CES1CA2P2RX7RIPK1 | |
| SCHEMBL2870153 | 0.75 | RIPK1 (0.45) | CES2CES1CA2P2RX7RIPK1 | |
| SCHEMBL2151373 | 0.75 | CES2 (0.43) | CES2CES1CA2P2RX7RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | CES2 4882/4885CES1 3679/4885CA2 4076/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | CES2 4885/4885CES1 4334/4885CA2 4491/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | CES2 4885/4885CES1 4334/4885CA2 4491/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | CES2 4885/4885CES1 4334/4885CA2 4491/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | CES2 4773/4885CES1 2321/4885CA2 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.